Clinical pharmacology of intermediate and low-dose cytosine arabinoside (ara-C) therapy in patients with hematologic malignancies.
Ueda
T
T
First Department of Internal Medicine, Fukui Medical School, Japan.
Matsuyama
S
S
Yamauchi
T
T
Kishi
S
S
Fukushima
T
T
Tsutani
H
H
Nakamura
T
T
Gotoh
N
N
Masada
M
M
D000368:Aged; D000369:Aged, 80 and over; D000964:Antimetabolites, Antineoplastic / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D001086:Arabinofuranosyluracil / Q000097:blood; D003561:Cytarabine / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D005260:Female; D019337:Hematologic Neoplasms / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008657:Metabolic Clearance Rate; D008875:Middle Aged
D000964:Antimetabolites, Antineoplastic; D003561:Cytarabine; D001086:Arabinofuranosyluracil